Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K, registration statements such as Form S‑1 and S‑1/A, proxy statements on Schedule 14A, and notifications of late filing on Form 12b‑25.
Through its filings, AIM ImmunoTech describes its business as an immuno-pharma company focused on research and development of therapeutics for cancers, viral diseases, and immune-deficiency disorders, with flagship products Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa. Registration statements and prospectuses detail capital-raising transactions, including offerings of common stock, pre‑funded warrants, Class E and Class F warrants, and rights offerings involving Series G Convertible Preferred Stock and warrants. These documents outline terms such as subscription rights, exercise prices, and use of proceeds.
Current reports on Form 8‑K capture material events, such as entry into a Note Purchase Agreement for an unsecured promissory note with an institutional investor, the closing of public offerings, the filing of corporate charter documents, and the release of corporate presentations. Filings also describe exchange listing matters, including temporary suspension of trading on the NYSE American, trading on the OTC Pink under a different symbol, and subsequent reinstatement on the NYSE American under the AIM symbol.
Investors can review notifications of late filing, such as Form 12b‑25, which explain delays in filing periodic reports and provide preliminary estimates of changes in revenues and net loss. Definitive proxy statements (DEF 14A) provide information on director elections, advisory votes on executive compensation, auditor ratification, and the company’s status as a smaller reporting company.
On Stock Titan, AIM ImmunoTech’s filings are updated as new documents are released on EDGAR. AI-powered summaries help explain the key points of lengthy filings, including risk factor discussions, financing structures, and governance proposals, so that readers can more quickly understand what each 10‑K, 10‑Q, 8‑K, or registration statement means for the company.
AIM ImmunoTech Inc. launched an at-the-market offering of up to $2,288,760 of common stock under a new Equity Distribution Agreement with Maxim Group LLC, acting as sales agent. Shares may be sold from time to time on the NYSE American or through other permitted methods, with Maxim earning a 3.0% commission on gross proceeds. The program is conducted under Form S-3 General Instruction I.B.6, which limits sales to one-third of the aggregate market value of non‑affiliate shares.
The company notes non‑affiliate market value of approximately $7,704,936 based on 2,675,325 non‑affiliate shares at $2.88 as of September 25, 2025, leaving $2,288,760 available under the cap. The last reported sale price was $2.62 on October 27, 2025. Shares outstanding were 2,764,188 as of October 27, 2025. On an illustrative basis, the company shows up to approximately 3,637,761 shares outstanding after this offering, assuming 873,573 shares sold at $2.62. Net proceeds, if any, will be used for working capital and general corporate purposes. The filing highlights risks including dilution, price volatility, and broad discretion in use of proceeds.
AIM ImmunoTech Inc. reported that it filed its amended and restated Certificate of Incorporation as Exhibit 3.1(i). The updated certificate is consolidated through October 29, 2025 and supersedes prior exhibit pieces.
The filing lists exhibits under Item 9.01 and includes the Cover Page Inline XBRL file. AIM’s common stock trades on the NYSE American under the symbol AIM.
AIM ImmunoTech Inc. filed its definitive proxy for the 2025 Annual Meeting. The virtual meeting is set for December 16, 2025 at 11:00 a.m. Eastern Time. Stockholders of record at the close of business on October 24, 2025 may vote; shares outstanding and entitled to vote were 2,764,188 as of the record date.
The Board recommends voting FOR all five director nominees—Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner, David I. Chemerow and William M. Mitchell—FOR ratification of BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2025, FOR approval, on an advisory basis, of named executive officer compensation, and selecting 1 YEAR for the frequency of future say‑on‑pay votes.
Directors will be elected by a plurality of votes cast; Proposals 2–4 require a majority in voting power of shares represented and entitled to vote. Quorum is 33 and 1/3% of shares entitled to vote. Proxies are being solicited by the Board; Sodali & Co. has been engaged to assist, for a fee of $20,000 plus expenses. AIM notes it is a smaller reporting company using scaled disclosures. Materials, including the 2024 Form 10‑K, are available via the company’s website and the SEC.
Form 8-K – Item 8.01. AIM ImmunoTech (AIM) disclosed a mid-year update from its ongoing Phase 2 DURIPANC trial evaluating Ampligen (rintatolimod) + AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer patients who achieved stable disease after FOLFIRINOX.
The Company characterizes the interim results as “positive,” but the filing does not provide numerical response, progression-free-survival or safety data. Full details are contained in Exhibit 99.1 (press release) and Exhibit 99.2 (clinical progress deck), which are incorporated by reference.
Investment takeaways:
- Positive clinical signal in a high-mortality indication may raise Ampligen’s probability of success and strengthen AIM’s oncology pipeline narrative.
- Collaboration with AstraZeneca lends external validation.
- No financial metrics, partnership economics or guidance were announced; commercial impact remains distant and dependent on future trials and regulatory approvals.
- Forward-looking-statement language underscores unresolved clinical, regulatory and funding risks.
AIM ImmunoTech has filed Amendment No. 4 to its Form S-1 to sell up to 1,052,631 Units—each containing one share (or a pre-funded warrant) plus a five-year Class E warrant and an 18-month Class F warrant—at an assumed $9.50 per Unit for gross proceeds of about $10 million. Maxim Group is acting on a reasonable best-efforts basis, earning a 7 % cash fee and placement-agent warrants equal to 5 % of the Units.
Estimated $9 million net proceeds will be directed to:
- working capital and payables
- clinical programs for Ampligen (pancreatic cancer, ME/CFS, post-COVID)
- manufacturing
- early repayment of a $310 k Streeterville bridge note
The company executed a 1-for-100 reverse split on 12 Jun 2025; trading on NYSE American resumed 17 Jun under “AIM.” Shares outstanding would rise from 0.764 m to 1.817 m post-offering, lifting as-adjusted book value from –$8.47 to $1.63 but creating immediate dilution of $7.87 per share.
At 31 Mar 2025 AIM’s stockholders’ equity was –$3.9 m, below the exchange’s $6 m threshold. The NYSE American has accepted a compliance plan running to 11 Jun 2026; successful capital raising is pivotal. The filing reiterates a going-concern warning, notes that the offering lacks a minimum or escrow, and highlights liquidity risks if proceeds fall short.
AIM ImmunoTech Inc. ("AIM") has filed a Form S-8 to register 15,283 additional shares of common stock for issuance under its Amended and Restated 2018 Equity Incentive Plan. The newly registered shares result from the plan’s evergreen provision, which automatically increases the share pool each 1 July by 2% of the company’s then-outstanding common stock. The filing incorporates by reference six prior S-8 registrations and the company’s periodic SEC reports, thereby limiting new disclosure to the incremental share registration and updated exhibits.
The Form S-8 is a routine administrative filing that enables AIM to continue granting equity awards to employees, directors and consultants without preparing a separate prospectus for each issuance. Key exhibits include the plan document, legal opinions and auditor consents. Because only 15,283 shares are being added, the transaction represents a small potential dilution to existing shareholders while supporting AIM’s ability to attract and retain talent through equity incentives.